DSc, Professor, Senior Vice President of Research Technology and Innovation, Chair of the Department of Cell Stress Biology at the Roswell Park Cancer Institute in the USA; specialist in oncology, virology, radiation biology, scientific founder and Scientific Director of the Cleveland Biolabs NASDAQ: CBLI, Incuron, Oncotartis, Everon Biosciences biochemical companies developing drugs to treat cancer, acute radiation syndrome and senescence.

In 1978, Pr. Gudkov graduated from the Department of Virology of the Biological Faculty of the Lomonosov Moscow State University.

In 1978–1982, he completed a PhD program at the Laboratory of Oncogenic Virus Immunology at the Cancer Research Center, where he continued to work as a junior researcher, senior researcher and head of a laboratory until 1990.

In 1982, Pr. Gudkov successfully defended his PhD thesis on experimental oncology, in 1988 – his DSc thesis on molecular biology.

Since 1990 he has been working in the USA. Until 2001 he worked at the Illinois University in Chicago, then for 7 year he headed the Department of Molecular Biology at the Cleveland Clinic. Since then he has worked at the Roswell Park Cancer Institute where in 2007 he became the Senior Vice President of Research Technology and Innovation and Chair of the Department of Cell Stress Biology. Since 2001 he has been working as a biochemistry professor at the Case Western Reserve University.

In 2007, Russian newspaper Novaya Gazeta called Pr. Gudkov “one of the most successful Russian biologists working abroad.”

Pr. Gudkov is a co-founder and editor-in-chief of the Oncotarget journal. He serves at the editorial boards of the Oncogene, Cancer Research, Aging and other journals. He is a member of the editorial board of the Bulletin of RSMU journal.

Pr. Gudkov has authored more than 200 scientific publications, holds more than 50 patents.